Trevi Therapeutics Unveils Exciting Developments for Haduvio Ahead of Major Healthcare Conference

Trevi Therapeutics: Key Updates Ahead of LifeSci Partners Event

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a company operating at the forefront of clinical-stage biopharmaceutical development, is making notable strides in the fight against chronic cough. On January 8, 2026, the company announced strategic plans in anticipation of its participation in the upcoming 15th Annual LifeSci Partners Corporate Access Event. This significant event will occur in San Francisco, CA, from January 12 to 14, 2026, coinciding with the prestigious J.P. Morgan Healthcare Conference week.

Jennifer Good, President and CEO of Trevi, expressed optimism as the company enters 2026. "As we begin this year, we look forward to advancing the clinical development of Haduvio, particularly for chronic cough indications," she stated. The company is preparing for an End-of-Phase 2 meeting with the FDA, scheduled for the first quarter of 2026. This meeting is crucial as it will guide the regulatory pathway for its New Drug Application regarding nalbuphine ER, specifically in patients suffering from idiopathic pulmonary fibrosis (IPF).

Key Developments on Chronic Cough in IPF

Trevi Therapeutics has received approval for an End-of-Phase 2 meeting with the FDA. This important dialogue will focus on the future of nalbuphine ER for chronic cough treatment within the IPF patient demographic. Following this meeting, the company plans to kick off its Phase 3 clinical program in the first half of 2026. There are approximately 150,000 patients in the U.S. diagnosed with IPF, and distressingly, two-thirds of these individuals struggle with chronic cough, underscoring the unmet medical need that Haduvio aims to address.

Advancements in Refractory Chronic Cough

In addition to its work on IPF, Trevi is also setting its sights on refractory chronic cough (RCC). With a Phase 2b trial slated to commence in the first half of 2026, the company is determined to explore new avenues in treating this challenging condition. RCC is defined as a persistent cough lasting more than eight weeks despite treatment for a recognized underlying condition and affects an estimated 2 to 3 million patients in the U.S. Due to the extensive impact of RCC on patients' daily lives—physically, psychologically, and socially—Trevi's efforts here hold significant promise.

David Hastings, recently appointed Chief Financial Officer, will join other senior management team members at the LifeSci Partners Corporate Access Event. This gathering serves as an excellent platform for Trevi to share its vision and updates with investors and stakeholders.

About Haduvio

Haduvio, an investigational oral formulation of nalbuphine, is being developed specifically for chronic cough associated with IPF, non-IPF interstitial lung disease (non-IPF ILD), and RCC. It uniquely acts on the cough reflex, providing a dual effect as a kappa agonist and mu antagonist (KAMA). This dual action targets opioid receptors linked to the regulation of chronic cough, marking Haduvio as a potential breakthrough in an area with limited treatment options.

Currently, chronic cough among IPF and non-IPF ILD patients remains inadequately managed, with no FDA-approved therapies available. The impact of a chronic cough on patients’ quality of life is profound, with some patients experiencing frequent coughing episodes reaching 1,500 times per day. Such persistent irritation can significantly impede daily functioning and elevate the risks of additional health complications, including increased morbidity and mortality.

Conclusion

As the year unfolds, Trevi Therapeutics is on a strategic path toward enhancing its drug development processes for Haduvio, especially as they engage with regulatory bodies and the medical community. The company’s commitment to combatting the challenges posed by chronic cough reflects a broader trend within biotechnology, seeking to address unmet medical needs with innovative solutions.

For ongoing updates and additional information, stakeholders can visit Trevi Therapeutics and follow them on social platforms like X (formerly Twitter) and LinkedIn. Through continued focus and determination, Trevi aims to make Haduvio a valuable option for patients suffering from these debilitating conditions.